Spots Global Cancer Trial Database for antibody
Every month we try and update this database with for antibody cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma | NCT03486067 | Multiple Myelom... | CC-93269 | 18 Years - | Celgene | |
| Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | NCT00635193 | Ovarian Cancer,... | M200 (Volocixim... Liposomal Doxor... M200 (Volocixim... M200 (Volocixim... | 18 Years - | AbbVie | |
| Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer | NCT02964078 | Kidney Cancer | Pembrolizumab Interleukin-2 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | NCT03250273 | Metastatic Chol... Cholangiocarcin... Pancreatic Canc... Metastatic Panc... Unresectable Pa... Unresectable Ch... | Entinostat Nivolumab Entinostat Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients | NCT00741377 | Multiple Myelom... | BHQ880 Zoledronic acid | 18 Years - 78 Years | Novartis | |
| Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | NCT02575222 | Clear Cell Rena... | Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Trial of PDL192 in Subjects With Advanced Solid Tumors | NCT00738764 | Cancer | PDL192 | 18 Years - | Abbott | |
| A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer | NCT00401570 | Pancreatic Canc... | Volociximab Gemcitabine | 18 Years - | AbbVie | |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | NCT02606305 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Mirvetuximab so... Bevacizumab Carboplatin Pegylated Lipos... Pembrolizumab | 18 Years - | ImmunoGen, Inc. | |
| Radioimmunotherapy With 131I-L19SIP in Patients With Cancer | NCT01242943 | Patients With C... | 131I-L19SIP Rad... | 18 Years - 75 Years | Philogen S.p.A. | |
| Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | NCT00444678 | Colorectal Canc... Neoplasm Metast... | Cetuximab Oxaliplatin Capecitabine | 18 Years - | NYU Langone Health | |
| Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer | NCT00857246 | Gastric Cancer Stomach Cancer | Cetuximab Irinotecan Cisplatin Surgery 5-FU Radiation | 18 Years - | NYU Langone Health | |
| L19TNFα in Patients With Advanced Solid Tumors | NCT01253837 | Solid Tumors Colorectal Canc... | L19TNFa | 18 Years - | Philogen S.p.A. | |
| Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma | NCT00383097 | Hodgkins Lympho... Non-Hodgkin Lym... | LMP1 SPECIFIC C... LMP2-SPECIFIC C... | - | Baylor College of Medicine | |
| Development of Serologic Assays for Human Herpes Virus-8 | NCT00395278 | Kaposi Sarcoma HIV Infection | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250 | NCT00199875 | Renal Cell Carc... Kidney Neoplasm Renal Cancer Kidney Cancer | Yttrium-90 conj... | 18 Years - | Ludwig Institute for Cancer Research | |
| PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | NCT01131247 | Chronic Lymphoc... | ofatumumab + be... | 18 Years - | Nevada Cancer Institute | |
| Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer | NCT02648282 | Pancreatic Canc... | Cyclophosphamid... GVAX Pancreatic... Pembrolizumab SBRT | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis | NCT04163419 | Schwannomatosis Pain | Tanezumab Placebo | 18 Years - | Massachusetts General Hospital | |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | NCT03711058 | Unresectable or... Colon Cancer | Copanlisib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma | NCT01137006 | Malignant Melan... | IMC-20D7S (Coho... IMC-20D7S (Coho... IMC-20D7S (Coho... IMC-20D7S (Coho... IMC-20D7S (Coho... IMC-20D7S (Coho... IMC-20D7S (Coho... | 18 Years - | Eli Lilly and Company | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | NCT00199797 | Colorectal Canc... | Oxaliplatin 5-Fluorouracil Leucovorin huA33 | 18 Years - | Ludwig Institute for Cancer Research | |
| Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer | NCT01443377 | Rectal Cancer | Panitumumab | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | NCT00625768 | Metastatic Rena... Metastatic Mali... | AS1409 | 18 Years - | Antisoma Research | |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | NCT00034138 | Ovarian Neoplas... | oregovomab | 18 Years - 65 Years | Unither Pharmaceuticals | |
| Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. | NCT00408967 | Ovarian Cancer | Tucotuzumab cel... | 18 Years - | EMD Serono | |
| 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC) | NCT01124812 | Non Small Cell ... | 131I-L19SIP Rad... | 18 Years - | Philogen S.p.A. | |
| Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis | NCT02144272 | Inflammatory Ar... | LY3114062 SC Placebo LY3114062 IV | 18 Years - 65 Years | Eli Lilly and Company | |
| Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. | NCT04909515 | Neuroblastoma | Naxitamab GM-CSF Isotretinoin | 1 Year - | Y-mAbs Therapeutics | |
| Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | NCT00679289 | Metastatic Mela... Cutaneous Melan... | HDI KW2871 KW2871 KW2871 | 18 Years - | Ludwig Institute for Cancer Research | |
| Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults | NCT04952766 | Kidney Transpla... Myeloma Cancer Hematologic Mal... Multiple Sclero... Hypergammaglobu... Malignant Tumor Hiv Diabetes Type 2 | Biological samp... | 18 Years - | Centre Hospitalier Régional d'Orléans | |
| A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | NCT03503604 | Solid Tumors | hPV19 mAb hPV19 mAb 5-Fluorouracil Oxaliplatin Leucovorin Paclitaxel Carboplatin Gemcitabine Carboplatin Irinotecan | 18 Years - 75 Years | SuZhou Stainwei Biotech Inc. | |
| A Trial of PDL192 in Subjects With Advanced Solid Tumors | NCT00738764 | Cancer | PDL192 | 18 Years - | Abbott | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer | NCT00199862 | Colorectal Neop... Colorectal Canc... Colorectal Tumo... COlorectal Carc... | Iodine-124 labe... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250 | NCT00199875 | Renal Cell Carc... Kidney Neoplasm Renal Cancer Kidney Cancer | Yttrium-90 conj... | 18 Years - | Ludwig Institute for Cancer Research | |
| A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer | NCT01240720 | Cancer | 131I-F16SIP Rad... | 18 Years - | Philogen S.p.A. | |
| Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer | NCT00034541 | Carcinoma, Non-... | cetuximab paclitaxel carboplatin | 18 Years - | Eli Lilly and Company | |
| Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | NCT00060684 | Lymphoma, Low-G... Lymphoma, Small... Lymphoma, Mixed... Lymphoma, Small... | Pixantrone (BBR... fludarabine dexamethasone rituximab | 18 Years - | CTI BioPharma | |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | NCT02109627 | Acute Myeloid L... Relapsed Acute ... Refractory Acut... | Ficlatuzumab Cytarabine | 18 Years - | University of California, San Francisco | |
| Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis | NCT02144272 | Inflammatory Ar... | LY3114062 SC Placebo LY3114062 IV | 18 Years - 65 Years | Eli Lilly and Company | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | NCT03727880 | Resectable Panc... Pancreatic Duct... | Pembrolizumab Defactinib | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) | NCT00593944 | Chronic Lymphoc... | MDX-1342 | 18 Years - | Bristol-Myers Squibb | |
| Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis | NCT02144272 | Inflammatory Ar... | LY3114062 SC Placebo LY3114062 IV | 18 Years - 65 Years | Eli Lilly and Company | |
| A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) | NCT00363636 | Lymphoma, Non-H... | Galiximab in co... Rituximab in co... | 18 Years - | Biogen | |
| Safety of AM-928 Infusion in Advanced Solid Tumors | NCT05687682 | Advanced Solid ... | AM-928 | 18 Years - | AcadeMab Biomedical Inc. | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China | NCT02586532 | Nasopharyngeal ... | 30 Years - 59 Years | National Institutes of Health Clinical Center (CC) | ||
| Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. | NCT04909515 | Neuroblastoma | Naxitamab GM-CSF Isotretinoin | 1 Year - | Y-mAbs Therapeutics | |
| Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | NCT00384150 | Lymphoma, Non-H... | galiximab in co... | 18 Years - | Biogen | |
| Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer | NCT00199862 | Colorectal Neop... Colorectal Canc... Colorectal Tumo... COlorectal Carc... | Iodine-124 labe... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | NCT00625768 | Metastatic Rena... Metastatic Mali... | AS1409 | 18 Years - | Antisoma Research | |
| Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma | NCT00651443 | Lymphoma, Non-H... | Galiximab | 18 Years - | Biogen | |
| Endoscopic Optical Imaging for Precision Oncology Treatment Applied to Colorectal Tumours (Elios-Color-on-Specimen) | NCT04101292 | Colorectal Canc... | Characterizatio... | 18 Years - | IHU Strasbourg | |
| Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer | NCT00836407 | Pancreatic Canc... | Ipilimumab Pancreatic Canc... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer | NCT04116073 | Pancreatic Canc... Pancreatic Canc... | INCMGA00012 (PD... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | NCT00060671 | Lymphoma, Folli... Lymphoma, Mixed... Lymphoma, Small... Lymphoma, Low-G... | rituximab Pixantrone (BBR... | 18 Years - | CTI BioPharma | |
| A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | NCT01963715 | EGFR Positive S... | IMGN289 | 18 Years - | ImmunoGen, Inc. | |
| A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | NCT03503604 | Solid Tumors | hPV19 mAb hPV19 mAb 5-Fluorouracil Oxaliplatin Leucovorin Paclitaxel Carboplatin Gemcitabine Carboplatin Irinotecan | 18 Years - 75 Years | SuZhou Stainwei Biotech Inc. | |
| DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC | NCT00496652 | Cancer of the H... | Radiotherapy Zalutumumab | 18 Years - | Danish Head and Neck Cancer Group | |
| Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) | NCT00593944 | Chronic Lymphoc... | MDX-1342 | 18 Years - | Bristol-Myers Squibb | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. | |
| Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00492830 | Cancer Neoplasm Metast... | TRC093 recombin... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | NCT03642067 | Microsatellite ... Colorectal Aden... | Nivolumab Relatlimab Nivolumab Relatlimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Clinical Trial for Ovarian Cancer (OvaRex®) | NCT00050375 | Ovarian Cancer | oregovomab | 18 Years - | Unither Pharmaceuticals | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | NCT03711058 | Unresectable or... Colon Cancer | Copanlisib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | NCT00034138 | Ovarian Neoplas... | oregovomab | 18 Years - 65 Years | Unither Pharmaceuticals | |
| Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. | NCT00199888 | Cancer of Kidne... Kidney Cancer Renal Cancer Neoplasms, Kidn... Renal Neoplasms Renal Cell Carc... Clear Cell Rena... | 124-Iodine-cG25... | 18 Years - | Ludwig Institute for Cancer Research | |
| Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | NCT00384150 | Lymphoma, Non-H... | galiximab in co... | 18 Years - | Biogen | |
| 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors | NCT01125085 | Brain Metastase... | 131I-L19SIP Rad... | 18 Years - | Philogen S.p.A. | |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | NCT00034138 | Ovarian Neoplas... | oregovomab | 18 Years - 65 Years | Unither Pharmaceuticals | |
| Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | NCT03071406 | Merkel Cell Car... Skin Cancer | Nivolumab Ipilimumab Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) | NCT00363636 | Lymphoma, Non-H... | Galiximab in co... Rituximab in co... | 18 Years - | Biogen | |
| Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | NCT03071406 | Merkel Cell Car... Skin Cancer | Nivolumab Ipilimumab Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas | NCT03153410 | Pancreatic Canc... | Cyclophosphamid... GVAX Pembrolizumab IMC-CS4 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours | NCT02076620 | Advanced Solid ... Sarcoma, Breast... | L19TNFα Doxorubicin | 18 Years - | Philogen S.p.A. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
